You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here Identifier : NCT03104413

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

    Status Recruiting
    Related Conditions
    Crohn's Disease

Enrollment Details

579 Worldwide Enrollment Goal


  • 1
  • 2
  • 3
  • 4
Study Type:  Interventional

This is a type III phase trial.

Protocol ID

Brief summary


The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Participant Attributes :
  • Male and Female
  • Ages 16 ans à 80 ans

Canada: 17

Calgary, AB
Edmonton, AB
Edmonton, AB
Edmonton, AB
New Westminster, BC
Vancouver, BC
Victoria, BC
Halifax, NS
Halifax, NS
London, ON
North Bay, ON
Sudbury, ON
Vaughan, ON
Greenfield Park, QC
Montreal, QC
Montreal, QC
Montreal, QC
Would you like to know more about this trial?

Study Design

  • The method used to assign participants to an arm of a clinical trial, for example Randomized (assigned by chance) versus Non-randomized.



  • The general design that shows how the medical interventions will be assigned to the participants, e.g., whether all patients will receive the same drug, or if different groups receive two or more different treatments in a particular order.

    Intervention Model

    Parallel Assignment

  • The general design that describes the strategy for identifying and following up with participants during observational studies.


    Double Blind (Subject/Investigator)

  • This is the single main reason for carrying out the clinical trial. Reasons can include: treatment, prevention, diagnostic advances, supportive care, screening, or health services research, among others.



    • Male or female aged >=18 to <= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit
    • Diagnosis of CD for at least 3 months prior to Baseline
    • Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD)
    • Demonstrated intolerance or inadequate response to biologic therapy for CD
    • If female, subject must meet the contraception recommendations
    • Subject with a current diagnosis of ulcerative colitis or indeterminate colitis
    • Subjects with unstable doses of concomitant Crohn's disease therapy
    • Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any investigational biologic or other agent or procedure within minimally 35 days or 5 half-lives prior to Baseline, whichever is longer.
    • Prior exposure to p19 inhibitors (e.g., risankizumab).
    • Complications of Crohn's disease (strictures, stenosis, short bowel, etc)
    • Having an ostomy or ileoanal pouch